Glioblastoma (GBM) stands as the most aggressive and lethal primary malignancy of the central nervous system, characterized by rapid infiltration, extensive angiogenesis, profound genomic instability, and a notoriously immunosuppressive tumor microenvironment. Despite decades of intensive research and significant advances in surgical techniques, radiation therapy, and chemotherapy, the prognosis for GBM patients remains dismal, with a median survival of approximately 15 months and a five-year survival rate below 10%. The recent revolution in cancer immunotherapy, particularly immune checkpoint inhibitors targeting the PD-1/PD-L1 axis, has transformed treatment for numerous malignancies including melanoma, lung cancer, and renal cell carcinoma. However, GBM has proven remarkably refractory to these immune-based interventions, with clinical trials largely failing to demonstrate significant survival benefit. This resistance stems from multiple factors including low mutational burden, highly immunosuppressive tumor microenvironment, blood-brain barrier, and fundamental lack of effective immunotherapeutic targets. Addressing this critical unmet need requires innovative approaches to identify novel therapeutic vulnerabilities. In this study, the research team employed a powerful CRISPR-based screening approach to systematically identify novel drivers of GBM progression. CRISPR-Cas9 technology has revolutionized functional genomics, enabling unbiased genome-scale screening to identify genes regulating cancer cell proliferation, survival, and therapeutic response. By applying this technology to GBM models, the researchers sought to uncover previously unrecognized therapeutic targets. The screen identified Niemann-Pick C1-like 1 (NPC1L1) as a prominent candidate, a gene best known for its role in intestinal cholesterol absorption and as the molecular target of ezetimibe, a widely prescribed cholesterol-lowering medication. While NPC1L1 has been implicated in certain cancers, its role in GBM had not been previously investigated, making this discovery both novel and potentially transformative. Mechanistic investigations revealed a sophisticated dual mechanism by which NPC1L1 drives GBM progression. NPC1L1 is a transmembrane protein that plays a critical role in cellular cholesterol homeostasis by mediating cholesterol uptake and intracellular trafficking. In GBM cells, the researchers found that NPC1L1 expression is significantly upregulated, and that NPC1L1 modulates cholesterol metabolism to enhance tumor cell stemness, a property closely associated with tumor initiation, therapeutic resistance, and recurrence. Cancer stem cells represent a small subpopulation with self-renewal capacity, widely believed responsible for treatment failure and disease recurrence in GBM. By promoting stemness, NPC1L1 contributes to the aggressive behavior and therapeutic resistance of GBM. Equally importantly, the study demonstrated that NPC1L1-mediated cholesterol metabolism suppresses CD8+ T-cell activation, creating an immunosuppressive tumor microenvironment that enables GBM cells to evade immune surveillance. CD8+ cytotoxic T cells are the primary effectors of anti-tumor immunity, and their functional suppression is a major mechanism of immunotherapy resistance. By concurrently promoting tumor cell stemness and suppressing anti-tumor immunity, NPC1L1 creates a powerful dual mechanism driving tumor progression while evading immune destruction. The translational potential of these findings is particularly compelling. Ezetimibe, an FDA-approved drug used clinically for over two decades to lower cholesterol by inhibiting NPC1L1, offers a readily available therapeutic agent that could be repurposed for GBM treatment. Drug repurposing represents an attractive strategy, leveraging existing safety and pharmacological data to significantly accelerate the path from bench to bedside. The researchers demonstrated that combined treatment with ezetimibe and anti-PD-1 antibody elicited potent antitumor activity in GBM orthotopic mouse models, significantly reducing tumor growth and extending survival compared to either treatment alone. This combination strategy addresses both arms of NPC1L1's pathogenic mechanism: ezetimibe inhibits NPC1L1-mediated cholesterol metabolism, reducing tumor cell stemness and relieving immune suppression, while anti-PD-1 therapy unleashes the suppressed CD8+ T-cell response. The synergistic effect highlights the potential of targeting cholesterol metabolism as a strategy to enhance immunotherapy efficacy in GBM. The implications extend beyond GBM to the broader field of cancer metabolism and immunotherapy. Cholesterol metabolism has emerged as a critical regulator of cancer biology, influencing cell proliferation, survival, membrane biosynthesis, and signal transduction. Increasing evidence suggests cholesterol metabolism also plays a pivotal role in shaping the tumor immune microenvironment, affecting both tumor and immune cell function. The identification of NPC1L1 as a key regulator linking cholesterol metabolism, tumor stemness, and immune suppression provides important insights into the complex interplay between metabolic reprogramming and immune evasion in cancer. Furthermore, the successful combination of ezetimibe with anti-PD-1 therapy offers a promising blueprint for developing metabolic-immunotherapy combination strategies applicable to other cancer types beyond GBM. In conclusion, this study represents a significant advance in GBM research, identifying NPC1L1 as a novel driver of GBM progression through a dual mechanism involving enhanced tumor cell stemness and suppressed CD8+ T-cell activation.
DOI
10.1007/s11684-026-1228-9